Structural formula of ibrutinib/ibrutinib

Ibrutinib/Ibrutinib is a kinase inhibitor. It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight of 440.50; its chemical name is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one. Ibrutinib is available in three forms: immediate-release oral capsules, immediate-release oral tablets, and immediate-release oral suspension.

Ibrutinib is a casein kinase inhibitor that slows or prevents the growth and spread of cancer cells by inhibiting the activity of an enzyme called Bruton casein kinase (BTK) in cancer cells. Specifically, ibrutinib interferes with the function of BTK in signaling pathways that play a key role in the proliferation and survival of leukemia and lymphoma cells. By inhibiting BTK, ibrutinib blocks the abnormal signaling of these malignant cells, reducing their ability to grow and spread.

Ibrutinib is widely used to treat adult chronic lymphocytic leukemia (CLL), relapsed or refractory small lymphocytic lymphoma (SLL), lymphocytic leukemia (MCL) and Waldenstrom macroglobulinemia (Waldenstrom macroglobulinemia) and other diseases. It is a targeted drug. Compared with traditional chemotherapy drugs, ibrutinib has higher selectivity and can act on cancer cells more precisely while reducing the impact on normal cells.

However, as a drug, ibrutinib may also cause some adverse reactions, such as fatigue, nausea, fever, hypothrombocytosis, etc. Therefore, before using ibrutinib, patients should be under the guidance of a physician and follow their recommendations for treatment.